PeppiLibrary

Growth Hormone

Ipamorelin peptide reference

Selective GH secretagogue. Cleaner pulse than older GHRPs.

Last reviewed May 6, 2026 Human data Not FDA approved
Peppi reviewing Ipamorelin notes
Default dose label300 mcg
Preferred routeSubQ
Frequency label1–3× daily
Storage window30 days mixed

Evidence snapshot

Human data

Evidence maturityHuman data
Animal and limited human studies

Research chemical (US)

Route map

How records are usually labeled

1 SubQ
2 IM

Rotate within the abdominal area to prevent localised desensitisation.

Vial timeline

Storage cues to log

Before mixRefrigerate 2–8 °C; freeze for long-term.
After mixRefrigerate 2–8 °C, use within 30 days.
Use-by cue30 days after mixing
Mixed vial window30 days
Use this as a record-keeping cue, not a replacement for product labeling.

Peppi workflow

From vial to review

Vial 5 mg vial
Dose 300 mcg
Route SubQ
Review 30d storage

Peppi turns scattered dose, vial, route, storage, note, and report details into one record trail.

Educational reference only

This page helps you understand what to track for Ipamorelin. It is not medical advice, a prescription, or a recommendation to use this peptide. Discuss dose, route, timing, storage, and safety with a qualified healthcare professional.

Overview

Ipamorelin is a pentapeptide developed by Novo Nordisk in 1998. It selectively activates the ghrelin receptor (GHS-R1a) in the pituitary, triggering GH release without significantly raising cortisol, prolactin or aldosterone — a cleaner profile than older GHRPs (GHRP-2, GHRP-6). Often stacked with a GHRH analog like CJC-1295 for synergy.

Also known as: NNC 26-0161.

GH support without cortisol/prolactin elevationRecovery and sleep qualityLean-mass support stacked with GHRH analogs

Mechanism and timing snapshot

Selective ghrelin/GHS-R1a receptor agonist on pituitary somatotrophs; triggers GH release without significant ACTH or prolactin elevation.

Onset label15 min
Catalog onset field, when available.
Half-life label2 hr
Effective half-life ~2 h
Duration label3 hr
Catalog duration field, when available.
subQ High
IM High
oral Negligible

Tracking defaults

These values come from Peppi's catalog so records can be prefilled consistently. They should be reviewed against your clinician's instructions before logging real-world use.

Catalog default dose300 mcg
Catalog dose range200 mcg - 500 mcg
Default routeSubQ
Frequency label1–3× daily
Best time labelPre-bed and/or post-workout, on an empty stomach.
Food noteAvoid food and high insulin within 30–60 min before or after dosing.

Catalog protocol note

200–300 mcg subQ pre-bed (and optionally post-workout) on an empty stomach, 5 days on / 2 off.

Routes and site notes

Available route labelsSubQ, IM
Preferred route labelSubQ
Common site labelsAbdomen
Site rotation noteRotate within the abdominal area to prevent localised desensitisation.

Chemistry

SequenceAib-His-D-2-Nal-D-Phe-Lys-NH2
Amino acids5
Molecular formulaC38H49N9O5
Molecular weight711.85 Da

Vial, reconstitution, and storage

Supply formLyophilized powder
Typical vial size5 mg
DiluentBacteriostatic water
Diluent volume2 mL
Concentration note5 mg in 2 mL → 0.12 mL = 300 mcg (12 units on a 100-unit insulin syringe).
Before reconstitutionRefrigerate 2–8 °C; freeze for long-term.
After reconstitutionRefrigerate 2–8 °C, use within 30 days.
Reconstituted shelf life30 days
Light sensitiveYes
Freeze/thaw warningYes

Safety notes

Common and rare side effects listed in the catalog

  • Mild head-rush or flushing
  • Hunger increase shortly after dosing
  • Vivid dreams when dosed pre-bed
  • Mild water retention
  • Tingling extremities

Contraindications and warnings

  • Active malignancy
  • Severe heart failure
  • Pregnancy
  • Sold as research-only in the US — not FDA-approved for human use.

Other considerations

  • Selective profile means fewer side effects than GHRP-2 or GHRP-6.
  • Hunger spike is short (~1 h) but can be intense in the first week.

Evidence and regulatory context

Evidence levelAnimal and limited human studies
FDA approvedNo
Regulatory statusResearch chemical (US)
Prescription requiredNo
Approved countriesNot listed

Stacking and cycle notes

Stacks well withcjc-1295, sermorelin
Avoid combining noteOther ghrelin agonists simultaneously
Typical cycle label8–12
Typical break label4
Cycle guidanceRun 8–12 week cycles with breaks to maintain receptor sensitivity.

Tracking tips

  • Pairs synergistically with CJC-1295 (no DAC) for a strong GH pulse.
  • Strict empty-stomach window (~60 min) is critical for full effect.
  • Hunger surge is normal — eat your scheduled meal after the pulse, not during.

References

Track it in Peppi

Keep Ipamorelin records organized.

Use Peppi for dose logs, vial inventory, storage dates, reminders, journal notes, photos, and clinician-ready reports.

Download on theApp Store Get it onGoogle Play

FAQ

What should I track for Ipamorelin?

Track the peptide name, dose amount and unit, route, vial label, timing, reconstitution or expiration dates, storage notes, and any symptoms or questions for clinician review.

Does Peppi tell me how to use Ipamorelin?

No. Peppi organizes educational reference and your own records. Protocol decisions should come from a qualified healthcare professional.

Can I export Ipamorelin records?

Peppi is designed to keep dose logs, vial inventory, journal notes, and reports easier to review and export.

Last reviewed: May 6, 2026